Total Funding
67
34
Total FundingSeed raised
Growth Score
-2 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
111832
DotBio develops multi-functional antibodies based on its proprietary DotBody technology as the next generation of cancer therapies.
Ignacio Nacho Asial: Founder, CEO
About the Company
DotBio develops multi-functional antibodies based on its proprietary DotBody technology as the next generation of cancer therapies. DotBio develops antibody therapies that target, at multiple junctions, the interplay between tumors and the tumor microenvironment to re-establish an effective immune response. Our proprietary technologies enable the
rapid generation of multi-specific antibodies targeting multiple processes. The rapid testing of combinatorial ensembles of multi-specific antibody prototypes can directly identify molecules re-activating the tumor immune response with novel synergistic mechanisms.
